New-onset atrial fibrillation post-surgery for esophageal and junctional cancer: strongly associated with complications, principally respiratory sepsis, and systemic inflammation


Retrospective cohort study from a prospective data base has assessed new-onset postoperative atrial fibrillation in patients with esophageal and junctional cancer.

Atrial fibrillation is common after thoracic and esophageal surgical procedures. The full spectrum of risk factors, associations, and implications are unclear.

All patients undergoing multimodal therapy or surgery with curative intent from 2006 to mid-2013 were studied. New-onset atrial fibrillation was recorded prospectively. Risk factors, management and resolution, association with other complications, and impact on in-hospital mortality and longer-term oncologic outcomes were analyzed in retrospective cohort analysis.

A total of 473 patients ( mean age: 63 years; 73% male ) underwent resection, 51% 2-stage, 18% 3-stage, 12% transhiatal, and 19% extended total gastrectomy.

Ninety-six ( 20% ) patients developed new-onset atrial fibrillation, in 18%, 27%, 29%, and 14% of 2-, 3-, transhiatal, and extended total gastrectomy cohorts, respectively ( P = 0.05 ).

Age, diabetes mellitus, neoadjuvant therapy, and cardiac history predisposed ( P less than 0.05 ) to atrial fibrillation, and atrial fibrillation was significantly ( P less than 0.0001 ) associated with pneumonia, pleural effusions requiring drainage, and maximum postoperative C-reactive protein ( CRP ) ( P less than 0.05 ) but not with anastomotic leak / conduit necrosis or mortality.

Amiodarone ( Cordarone ) was the primary treatment in 63% of cases, 1% underwent cardioversion, and 92% were in sinus rhythm on discharge.

At a median follow-up of 40 months ( 7-109 months ), the median survival was 40 months versus 53 months in the atrial fibrillation and non-atrial fibrillation cohorts, respectively ( P = 0.353 ).

In conclusion, new-onset atrial fibrillation is common, linked to age, diabetes mellitus, cardiac disease, and neoadjuvant therapy. It is strongly associated with complications, principally respiratory sepsis, and systemic inflammation.
For most, it resolves, with no impact on oncologic outcomes. ( Xagena )

Mc Cormack O et al, Ann Surg 2014;260:772-778

XagenaMedicine_2014



Indietro

Altri articoli

Atrial fibrillation is the most frequent sustained arrhythmia. Atrial fibrillation often recurs after restoration of normal sinus rhythm. Antiarrhythmic drugs...


Available pharmacological options for rhythm control strategy in atrial fibrillation are limited by sub-optimal efficacy and potentially serious adverse events....


Randomized controlled trials ( RCTs ) regarding use of Ranolazine for the prevention and cardioversion of atrial fibrillation have yielded...


Catheter ablation of ventricular tachycardia in patients with nonischemic dilated cardiomyopathy can be challenging because of the complexity of underlying...


The clinical efficacy and toxicity of Amiodarone ( Cordarone ) may be determined more effectively by tissue deposition than by...


Although there are many different antiarrhythmic drugs approved for rhythm management of atrial fibrillation, little comparative effectiveness data exist to...


Amiodarone ( Cordarone ) is known to affect the thyroid, but little is known about thyroid recovery after short-term Amiodarone...


Sotalol ( Sotalex ) and Amiodarone ( Cordarone ) are commonly prescribed antiarrhythmics for the treatment of post-operative atrial fibrillation...


Ibutilide ( Corvert ) is a rapid-acting antiarrhythmic drug with worldwide use for conversion of recent-onset atrial fibrillation. Vernakalant (...


The 2015 Guidelines for Resuscitation recommend Amiodarone ( Cordarone ) as the antiarrhythmic drug of choice in the treatment of...